within Pharmacolibrary.Drugs.ATC.J;

model J05AP03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 0.2733333333333333,
    adminDuration  = 600,
    adminMass      = 0.8,
    adminCount     = 1,
    Vd             = 0.193,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Boceprevir is a direct-acting antiviral drug that inhibits the NS3/4A serine protease of hepatitis C virus (HCV). It was used in combination with other antiviral drugs (such as peginterferon alfa and ribavirin) for the treatment of chronic HCV infection, specifically genotype 1. Boceprevir was approved by the FDA in 2011 but has been discontinued and is no longer marketed due to newer, more effective HCV medications with better safety profiles.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for healthy adult subjects (both sexes), after multiple oral doses of 800 mg three times daily.</p><h4>References</h4><ol><li>S A Rizza, R Talwani, V Nehra, Z Temesgen,Boceprevir.,Drugs of today (Barcelona, Spain : 1998),2011<a href='https://pubmed.ncbi.nlm.nih.gov/22076489/'>https://pubmed.ncbi.nlm.nih.gov/22076489/</a></li><li>Mark Johnson, Julie Borland, Shuguang Chen, Paul Savina, Brian Wynne, Stephen Piscitelli,Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir.,British journal of clinical pharmacology,2014<a href='https://pubmed.ncbi.nlm.nih.gov/24838177/'>https://pubmed.ncbi.nlm.nih.gov/24838177/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AP03;
